These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1421051)

  • 21. Pharmacokinetics of a single intravenous dose of teicoplanin in subjects with various degrees of renal impairment.
    Bonati M; Traina GL; Rosina R; Buniva G
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():29-37. PubMed ID: 2965129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of teicoplanin in subjects with varying degrees of renal function.
    Derbyshire N; Webb DB; Roberts D; Glew D; Williams JD
    J Antimicrob Chemother; 1989 Jun; 23(6):869-76. PubMed ID: 2527223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
    Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections.
    Nakamura A; Takasu O; Sakai Y; Sakamoto T; Yamashita N; Mori S; Morita T; Nabeta M; Hirayu N; Yoshiyama N; Moroki M; Tashiro K; Kannae M
    J Infect Chemother; 2015 Jun; 21(6):449-55. PubMed ID: 25726436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function.
    Gasser TC; Ebert SC; Graversen PH; Madsen PO
    Antimicrob Agents Chemother; 1987 May; 31(5):709-12. PubMed ID: 3300537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teicoplanin pharmacokinetics and dosage recommendations in chronic hemodialysis patients and in patients undergoing continuous veno-venous hemodialysis.
    Wolter K; Claus M; Wagner K; Fritschka E
    Clin Nephrol; 1994 Dec; 42(6):389-97. PubMed ID: 7882603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
    Periclou A; Ventura D; Rao N; Abramowitz W
    Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function.
    Guay DR; Matzke GR; Bockbrader HN; Dancik J
    Clin Pharm; 1983; 2(2):157-62. PubMed ID: 6883944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.
    Zhao W; Zhang D; Storme T; Baruchel A; Declèves X; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2015 Nov; 80(5):1197-207. PubMed ID: 26138279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients.
    Rouan MC; Binswanger U; Bammatter F; Theobald W; Schoeller JP; Guibert J
    J Antimicrob Chemother; 1984 Jun; 13(6):611-8. PubMed ID: 6088464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
    Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
    J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme.
    Lamont E; Seaton RA; Macpherson M; Semple L; Bell E; Thomson AH
    J Antimicrob Chemother; 2009 Jul; 64(1):181-7. PubMed ID: 19411678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of teicoplanin in renal failure.
    Falcoz C; Ferry N; Pozet N; Cuisinaud G; Zech PY; Sassard J
    Antimicrob Agents Chemother; 1987 Aug; 31(8):1255-62. PubMed ID: 2957955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
    Gretler DD; Guerciolini R; Williams PJ
    Clin Ther; 2004 Mar; 26(3):390-8. PubMed ID: 15110131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of renal function on risedronate pharmacokinetics after a single oral dose.
    Mitchell DY; St Peter JV; Eusebio RA; Pallone KA; Kelly SC; Russell DA; Nesbitt JD; Thompson GA; Powell JH
    Br J Clin Pharmacol; 2000 Mar; 49(3):215-22. PubMed ID: 10718776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
    Nilsen OG; Saltvedt E; Walstad RA; Marstein S
    Am J Med; 1992 Apr; 92(4A):38S-40S. PubMed ID: 1316068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics.
    Niwa T; Imanishi Y; Ohmori T; Matsuura K; Murakami N; Itoh Y
    Int J Antimicrob Agents; 2010 May; 35(5):507-10. PubMed ID: 20185275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections.
    Wang JT; Liao HI; Wu Lin FL; Chang SC
    Basic Clin Pharmacol Toxicol; 2012 May; 110(5):416-20. PubMed ID: 22309355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of teicoplanin in the elderly.
    Rosina R; Villa G; Danese A; Cavenaghi L; Picardi L; Salvadeo A
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():39-45. PubMed ID: 2965130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
    Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
    Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.